Quotient Clinical has announced an agreement with Medigene to undertake a Rapidfact formulation development and clinical testing programme on Rhudex.
This is subject to ethical and Medicines and Healthcare Products Regulatory Agency approval.
Rhudex is a potential first-in-class treatment for rheumatoid arthritis and other inflammatory disorders.
Quotient Clinical's Rapidfact service makes use of its tightly integrated GMP manufacturing and clinical testing processes and facilities to enable the rapid clinical evaluation of new drug formulations.
Rapidfact is said to enable shortening of project timelines and a reduction of ~90 per cent in API consumption.
Medigene will use the drug formulation selected in this programme as the basis for the further clinical development of Rhudex.
